Article Text

Download PDFPDF
Paroven: not much effect in trials


The Medicines Control Agency has recently restricted the licensed uses of Paroven (Zyma*) to ‘relief of symptoms of oedema associated with chronic venous insufficiency’. A mixture of oxerutins, Paroven had long been marketed for the relief of symptoms ‘associated with venous insufficiency, including painful heavy tired legs, night cramps, paraesthesia, restless legs, varicose states, and post-phlebitic syndrome’. Much work on the drug has been published since 1970, when we concluded that despite interesting pharmacological actions the evidence for its therapeutic value was poor.1 Is there now a clear rationale for its use?

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • * Zyma is a subsidiary of Ciba-Geigy